vs
Side-by-side financial comparison of Allstate (ALL) and Hologic (HOLX). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $922.0M, roughly 1.1× Allstate). Allstate runs the higher net margin — 266.6% vs 17.1%, a 249.5% gap on every dollar of revenue. On growth, Allstate posted the faster year-over-year revenue change (7.2% vs 2.5%). Over the past eight quarters, Hologic's revenue compounded faster (1.5% CAGR vs -75.8%).
The Allstate Corporation, together with its subsidiaries, provides property and casualty, and other insurance products in the United States and Canada. The company operates through Allstate Protection; Protection Services; Allstate Health and Benefits; and Run-off Property-Liability segments. The Allstate Protection segment offers private passenger auto and homeowners insurance; specialty auto products, including motorcycle, trailer, motor home, and off-road vehicle insurance; other personal ...
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
ALL vs HOLX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $922.0M | $1.0B |
| Net Profit | $2.5B | $179.1M |
| Gross Margin | — | 56.0% |
| Operating Margin | -1400.3% | 22.6% |
| Net Margin | 266.6% | 17.1% |
| Revenue YoY | 7.2% | 2.5% |
| Net Profit YoY | — | -10.9% |
| EPS (diluted) | $9.25 | $0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $922.0M | — | ||
| Q4 25 | $17.3B | $1.0B | ||
| Q3 25 | $17.3B | $1.0B | ||
| Q2 25 | $16.6B | $1.0B | ||
| Q1 25 | $16.5B | $1.0B | ||
| Q4 24 | $16.5B | $1.0B | ||
| Q3 24 | $16.6B | $988.0M | ||
| Q2 24 | $15.7B | $1.0B |
| Q1 26 | $2.5B | — | ||
| Q4 25 | $3.8B | $179.1M | ||
| Q3 25 | $3.7B | $187.2M | ||
| Q2 25 | $2.1B | $194.9M | ||
| Q1 25 | $595.0M | $-17.4M | ||
| Q4 24 | $1.9B | $201.0M | ||
| Q3 24 | $1.2B | $178.6M | ||
| Q2 24 | $331.0M | $194.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | 56.0% | ||
| Q3 25 | — | 55.6% | ||
| Q2 25 | — | 56.3% | ||
| Q1 25 | — | 37.5% | ||
| Q4 24 | — | 56.8% | ||
| Q3 24 | — | 56.4% | ||
| Q2 24 | — | 55.4% |
| Q1 26 | -1400.3% | — | ||
| Q4 25 | — | 22.6% | ||
| Q3 25 | — | 22.6% | ||
| Q2 25 | — | 24.9% | ||
| Q1 25 | — | -0.7% | ||
| Q4 24 | — | 22.5% | ||
| Q3 24 | — | 23.3% | ||
| Q2 24 | — | 24.1% |
| Q1 26 | 266.6% | — | ||
| Q4 25 | 22.1% | 17.1% | ||
| Q3 25 | 21.7% | 17.8% | ||
| Q2 25 | 12.7% | 19.0% | ||
| Q1 25 | 3.6% | -1.7% | ||
| Q4 24 | 11.7% | 19.7% | ||
| Q3 24 | 7.2% | 18.1% | ||
| Q2 24 | 2.1% | 19.2% |
| Q1 26 | $9.25 | — | ||
| Q4 25 | $14.24 | $0.79 | ||
| Q3 25 | $13.95 | $0.84 | ||
| Q2 25 | $7.76 | $0.86 | ||
| Q1 25 | $2.11 | $-0.08 | ||
| Q4 24 | $7.07 | $0.87 | ||
| Q3 24 | $4.33 | $0.75 | ||
| Q2 24 | $1.13 | $0.82 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $2.4B |
| Total DebtLower is stronger | — | $2.5B |
| Stockholders' EquityBook value | $31.6B | $5.2B |
| Total Assets | $124.0B | $9.2B |
| Debt / EquityLower = less leverage | — | 0.48× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $4.9B | $2.4B | ||
| Q3 25 | $8.7B | $2.2B | ||
| Q2 25 | $9.6B | $1.9B | ||
| Q1 25 | $6.5B | $1.6B | ||
| Q4 24 | $4.5B | $2.0B | ||
| Q3 24 | $7.0B | $2.3B | ||
| Q2 24 | $5.3B | $2.4B |
| Q1 26 | — | — | ||
| Q4 25 | $7.5B | $2.5B | ||
| Q3 25 | $8.1B | $2.5B | ||
| Q2 25 | $8.1B | $2.5B | ||
| Q1 25 | $8.1B | $2.5B | ||
| Q4 24 | $8.1B | $2.5B | ||
| Q3 24 | $8.1B | $2.5B | ||
| Q2 24 | $8.1B | $2.5B |
| Q1 26 | $31.6B | — | ||
| Q4 25 | $30.6B | $5.2B | ||
| Q3 25 | $27.5B | $5.0B | ||
| Q2 25 | $24.0B | $4.8B | ||
| Q1 25 | $22.1B | $4.6B | ||
| Q4 24 | $21.4B | $4.8B | ||
| Q3 24 | $20.9B | $5.1B | ||
| Q2 24 | $18.6B | $5.0B |
| Q1 26 | $124.0B | — | ||
| Q4 25 | $119.8B | $9.2B | ||
| Q3 25 | $120.4B | $9.0B | ||
| Q2 25 | $115.9B | $8.8B | ||
| Q1 25 | $115.2B | $8.5B | ||
| Q4 24 | $111.6B | $8.7B | ||
| Q3 24 | $113.7B | $9.2B | ||
| Q2 24 | $108.4B | $8.9B |
| Q1 26 | — | — | ||
| Q4 25 | 0.24× | 0.48× | ||
| Q3 25 | 0.29× | 0.50× | ||
| Q2 25 | 0.34× | 0.52× | ||
| Q1 25 | 0.37× | 0.55× | ||
| Q4 24 | 0.38× | 0.53× | ||
| Q3 24 | 0.39× | 0.49× | ||
| Q2 24 | 0.43× | 0.51× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $229.9M |
| Free Cash FlowOCF − Capex | — | $215.2M |
| FCF MarginFCF / Revenue | — | 20.5% |
| Capex IntensityCapex / Revenue | — | 1.4% |
| Cash ConversionOCF / Net Profit | — | 1.28× |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $3.0B | $229.9M | ||
| Q3 25 | $3.3B | $355.1M | ||
| Q2 25 | $1.9B | $343.3M | ||
| Q1 25 | $2.0B | $169.4M | ||
| Q4 24 | $1.7B | $189.3M | ||
| Q3 24 | $3.2B | $367.0M | ||
| Q2 24 | $2.4B | $405.8M |
| Q1 26 | — | — | ||
| Q4 25 | $2.9B | $215.2M | ||
| Q3 25 | $3.2B | $341.4M | ||
| Q2 25 | $1.9B | $330.5M | ||
| Q1 25 | $1.9B | $153.9M | ||
| Q4 24 | $1.7B | $172.5M | ||
| Q3 24 | $3.1B | $350.6M | ||
| Q2 24 | $2.3B | $385.3M |
| Q1 26 | — | — | ||
| Q4 25 | 16.7% | 20.5% | ||
| Q3 25 | 18.8% | 32.5% | ||
| Q2 25 | 11.3% | 32.3% | ||
| Q1 25 | 11.4% | 15.3% | ||
| Q4 24 | 10.0% | 16.9% | ||
| Q3 24 | 18.9% | 35.5% | ||
| Q2 24 | 14.7% | 38.1% |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 1.4% | ||
| Q3 25 | 0.3% | 1.3% | ||
| Q2 25 | 0.0% | 1.3% | ||
| Q1 25 | 0.6% | 1.5% | ||
| Q4 24 | 0.3% | 1.6% | ||
| Q3 24 | 0.4% | 1.7% | ||
| Q2 24 | 0.4% | 2.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.78× | 1.28× | ||
| Q3 25 | 0.88× | 1.90× | ||
| Q2 25 | 0.89× | 1.76× | ||
| Q1 25 | 3.30× | — | ||
| Q4 24 | 0.88× | 0.94× | ||
| Q3 24 | 2.69× | 2.05× | ||
| Q2 24 | 7.13× | 2.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALL
Segment breakdown not available.
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
